Parexel International is being snapped up by private equity group Pamplona Capital Management in a deal valued at around $5 billion, including debt, marking further consolidation of the contract research sector. The groups have signed a definitive agreement under which Pamplona will acquire all of the outstanding shares of the global biopharmaceutical services provider for $88.10 per share in cash.
For the first time in 10 years global sales of pharmaceuticals are forecast by Evaluate to take a downturn because of growing pricing pressures.Analysts at the group are projecting that sales will hit $1.06 trillion in 2022, down from the $1.12 trillion forecast last year for the same period.
HealthTech firm Now Healthcare Group (NHG) has secured £4m in Series A funding from Medicash, a health cash plan provider based in Liverpool, in exchange for a minority stake in the business.
Sinclair Pharma plc (SPH.L), (“Sinclair”) the international aesthetics company, is pleased to announce it has acquired the Refine™ Support System, a patented and FDA cleared, suture based product primarily used in breast cosmetic and reconstructive procedures for a total consideration of up to $11.3m including regulatory and sales based milestones and royalties.
Consort Medical plc (LSE: CSRT) (“Consort”, “Consort Medical” or the “Group”), a leading, global, single source drug and delivery device company, today announces its audited results for the year ended 30 April 2017.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that researchers from Queen Mary University of London’s Barts Cancer Institute (BCI), using ANGLE’s Parsortix system, have found a rare cell, known as a megakaryocyte, in the blood of prostate cancer patients and discovered that the number of these cells in the blood correlates closely with increased patient survival.
Taking the stress out of stocks…
New AIM listed biotech firm Oxford Biodynamics reported first set of results as listed company today. After the period end, though it signed up two top global pharmas, and inked licence deals in Asia, so could it be an early stock to buy? Plus even billionaires can find it tough going with the neighbours…
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces the successful completion of the Placing (as defined below) which was announced earlier today.
Motif Bio plc (AIM:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces its intention to raise approximately £19.4 million (US$25 million), before expenses, by way of a conditional placing with new and existing investors to fund the further development of iclaprim, the Company’s novel antibiotic candidate.
Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an announcement made by Sierra Oncology, Inc. yesterday stating that selection patents* that explicitly protect the Chk1 inhibitor SRA737 have been granted in the USA and Europe, extending its protection period to the year 2033 in the US.